JNJ-42847922
Sponsors
Janssen Cilag International, Janssen Research & Development, LLC, Janssen Cilag N.V./S.A., Janssen-Cilag International NV
Conditions
Depressive Disorder, MajorHealthyHepatic ImpairmentInsomniaMajor Depressive DisorderMajor Depressive Disorder with Insomnia SymptomsRenal Impairment
Phase 1
A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
CompletedNCT02067299
Start: 2014-02-28End: 2014-12-31Updated: 2016-02-04
Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants
CompletedNCT02455856
Start: 2015-05-18End: 2015-06-19Updated: 2017-07-11
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
CompletedNCT02475161
Start: 2015-06-30End: 2015-07-31Updated: 2025-02-03
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
CompletedNCT02476058
Start: 2015-06-11End: 2016-01-04Updated: 2025-04-27
Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants
CompletedNCT02578472
Start: 2015-11-30End: 2016-02-29Updated: 2016-03-24
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
CompletedNCT02617810
Start: 2015-11-30End: 2016-02-29Updated: 2016-02-23
A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
CompletedNCT02661893
Start: 2016-01-31End: 2016-02-29Updated: 2025-02-03
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
CompletedNCT03249402
Start: 2017-08-14End: 2017-11-24Updated: 2025-04-27
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
CompletedNCT04616677
Start: 2021-03-31End: 2022-10-18Updated: 2025-04-27
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
CompletedNCT04960124
Start: 2021-08-05End: 2021-11-19Updated: 2025-04-27
Phase 2
Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity
CompletedNCT02464046
Start: 2015-07-27End: 2015-12-02Updated: 2025-04-27
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
CompletedNCT03227224
Start: 2017-08-16End: 2019-01-19Updated: 2025-04-29
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
CompletedNCT03321526
Start: 2017-12-12End: 2019-06-27Updated: 2025-04-29